×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OPRX – optimizerx corporation (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OPRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/10
10:15 am
oprx
OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 [Seeking Alpha]
Neutral
Report
OptimizeRx: Q4 Earnings Report Indicates Caution For 2026 [Seeking Alpha]
3/6
07:03 pm
oprx
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
Low
Report
OptimizeRx Corp (OPRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... [Yahoo! Finance]
3/6
03:52 pm
oprx
OptimizeRx (OPRX) had its price target lowered by Lake Street Capital from $24.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
OptimizeRx (OPRX) had its price target lowered by Lake Street Capital from $24.00 to $20.00. They now have a "buy" rating on the stock.
3/6
12:59 pm
oprx
OptimizeRx (OPRX) had its price target lowered by Roth Mkm from $32.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
OptimizeRx (OPRX) had its price target lowered by Roth Mkm from $32.00 to $18.00. They now have a "buy" rating on the stock.
3/6
12:25 pm
oprx
OptimizeRx (OPRX) had its "buy" rating reaffirmed by B. Riley Financial, Inc.. They now have a $11.00 price target on the stock, down from $28.00.
Medium
Report
OptimizeRx (OPRX) had its "buy" rating reaffirmed by B. Riley Financial, Inc.. They now have a $11.00 price target on the stock, down from $28.00.
3/6
10:59 am
oprx
OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.
Medium
Report
OptimizeRx (OPRX) had its price target lowered by Stephens from $17.00 to $10.00. They now have an "equal weight" rating on the stock.
3/6
10:11 am
oprx
OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.
Medium
Report
OptimizeRx (OPRX) was given a new $17.00 price target by Stifel Nicolaus.
3/5
11:21 pm
oprx
OptimizeRx Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
OptimizeRx Q4 Earnings Call Highlights [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/12
04:05 pm
oprx
Form 10-K OptimizeRx Corp For: Dec 31
Medium
Report
Form 10-K OptimizeRx Corp For: Dec 31
3/5
04:10 pm
oprx
Form 8-K OptimizeRx Corp For: Mar 05
High
Report
Form 8-K OptimizeRx Corp For: Mar 05
2/13
11:50 am
oprx
Form 4 OptimizeRx Corp For: Feb 11 Filed by: Odence-Ford Marion
Low
Report
Form 4 OptimizeRx Corp For: Feb 11 Filed by: Odence-Ford Marion
12/23
05:43 pm
oprx
Form 4/A OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L
Low
Report
Form 4/A OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L
12/23
04:55 pm
oprx
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L
Low
Report
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Silvestro Stephen L
12/23
04:55 pm
oprx
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Greco Theresa
Low
Report
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Greco Theresa
12/23
04:54 pm
oprx
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Odence-Ford Marion
Low
Report
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Odence-Ford Marion
12/23
04:53 pm
oprx
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Besch Doug
Low
Report
Form 4 OptimizeRx Corp For: Dec 23 Filed by: Besch Doug
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form NT 10-K OptimizeRx Corp For: Dec 31
31.9%
12/9 OptimizeRx Sales Pipeline Up 79% to $84 Million in 2019; Company Reiterates Strong Q4 and 2020 Outlook 16.4%
5/8 Q1/2019 3/31/2019 EPS 0.060 ZacksConsensus -0.010 ActVsEst 0.070 - Beat 15.6%
1/29 OptimizeRx Seals Multi-Million Dollar Enterprise Deal for Integrated Platform 13.2%
3/6 Form 8-K OptimizeRx Corp For: Mar 05 8.8%
4/16 OptimizeRx Sets First Quarter 2020 Conference Call for Monday, May 4, 2020 at 4:30 p.m. ET 8.7%
8/7 Q2/2019 6/30/2019 EPS 0.090 ZacksConsensus 0.030 ActVsEst 0.060 - Beat 8.4%
5/14 OptimizeRx Co. (NASDAQ: OPRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $16.00 price target on the stock. 6.9%
3/12 Form 8-K OptimizeRx Corp For: Mar 11 6.8%
3/10 OptimizeRx Launches ‘Digital Healthcare’ Webinar Series 5.8%
12/9 OptimizeRx Sales Pipeline Up 79% to $84 Million in 2019; Company Reiterates Strong Q4 and 2020 Outlook 16.4%
5/8 Q1/2019 3/31/2019 EPS 0.060 ZacksConsensus -0.010 ActVsEst 0.070 - Beat 15.6%
1/29 OptimizeRx Seals Multi-Million Dollar Enterprise Deal for Integrated Platform 13.2%
3/6 Form 8-K OptimizeRx Corp For: Mar 05 8.8%
4/16 OptimizeRx Sets First Quarter 2020 Conference Call for Monday, May 4, 2020 at 4:30 p.m. ET 8.7%
8/7 Q2/2019 6/30/2019 EPS 0.090 ZacksConsensus 0.030 ActVsEst 0.060 - Beat 8.4%
5/14 OptimizeRx Co. (NASDAQ: OPRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $16.00 price target on the stock. 6.9%
3/12 Form 8-K OptimizeRx Corp For: Mar 11 6.8%
3/10 OptimizeRx Launches ‘Digital Healthcare’ Webinar Series 5.8%
TOP News Decliners
4/17
OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating.
-27.7%
2/28 Form 8-K OptimizeRx Corp For: Feb 27 -18.5%
3/18 OptimizeRx to Host Online Session with Clinical Leaders at Microsoft, Massachusetts General Hospital and BD -15.7%
11/5 Q3/2019 9/30/2019 EPS -0.050 ZacksConsensus 0.060 ActVsEst (0.110) - Miss -13.8%
3/26 Form 10-K OptimizeRx Corp For: Dec 31 -9.6%
3/9 OptimizeRx Digital Health Network Now Delivering CDC Coronavirus Alerts to Thousands of Healthcare Providers Nationwide -9.0%
3/13 Form 4 OptimizeRx Corp For: Mar 11 Filed by: BAKER DOUGLAS P -7.6%
1/18 OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.7%
11/5 OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.4%
8/9 OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.7%
2/28 Form 8-K OptimizeRx Corp For: Feb 27 -18.5%
3/18 OptimizeRx to Host Online Session with Clinical Leaders at Microsoft, Massachusetts General Hospital and BD -15.7%
11/5 Q3/2019 9/30/2019 EPS -0.050 ZacksConsensus 0.060 ActVsEst (0.110) - Miss -13.8%
3/26 Form 10-K OptimizeRx Corp For: Dec 31 -9.6%
3/9 OptimizeRx Digital Health Network Now Delivering CDC Coronavirus Alerts to Thousands of Healthcare Providers Nationwide -9.0%
3/13 Form 4 OptimizeRx Corp For: Mar 11 Filed by: BAKER DOUGLAS P -7.6%
1/18 OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -6.7%
11/5 OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -4.4%
8/9 OptimizeRx Co. (NASDAQ: OPRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -3.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: